Roche enters obesity drug market with $2.7 bln Carmot deal | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 04, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 04, 2025
Roche enters obesity drug market with $2.7 bln Carmot deal

World+Biz

Reuters
04 December, 2023, 03:35 pm
Last modified: 04 December, 2023, 03:38 pm

Related News

  • UN report identifies the drugs most prevalent worldwide
  • Govt yet to bring drug abuse and corruption under control: Home adviser
  • Philippine Navy seizes $175 million meth haul at sea
  • Health reform commission, drug ingredient makers push for pharma self-reliance
  • Trump says US will soon announce tariffs on pharmaceutical imports

Roche enters obesity drug market with $2.7 bln Carmot deal

Reuters
04 December, 2023, 03:35 pm
Last modified: 04 December, 2023, 03:38 pm
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo

Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly.

On top of the upfront purchase price of $2.7 billion, Carmot's equity holders will receive payments of up to $400 million if certain milestones are achieved, the Swiss drugmaker said in a statement on Monday.

The takeover target's most promising drug candidate CT-388 belongs to a class known as a dual GLP-1/GIP receptor agonist, the same as Lilly's (LLY.N) Mounjaro, or Zepbound.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added.

Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene.

New Roche CEO Thomas Schinecker has set a high deal pace since taking the helm in March to restore Roche's drug development pipeline, which hit major late-stage trial setbacks in Alzheimer's and cancer immunotherapy last year.

Roche in October agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, eyeing new therapeutic fields to offset falling oncology sales.

Carmot's current portfolio includes clinical stage gut-hormone drugs, in pill and injection form, aimed at treating obesity in patients with and without diabetes, as well as a number of preclinical programmes, Roche said.

Carmot's employees will join Roche's pharmaceuticals division when the transaction officially closes, expected in the first quarter of 2024.

Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Global Economy

pharmaceutical / Drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Ships and shipping containers are pictured at the port of Long Beach in Long Beach, California, US, 30 January 2019. Photo: REUTERS
    Bangladesh expects US tariff relief after Trump's cuts to Vietnam
  • Local spinners produce export-standard carded and combed yarn. Photo: Mumit M
    Will higher taxes drive up RMG's yarn import reliance?
  • Screengrab from a CCTV video shows a chaotic moment as several individuals chase a woman down a staircase inside a hotel in Dhaka's Mohalhali on 1 July 2025
    Jubo Dal leader expelled over alleged attack on women in Mohakhali hotel

MOST VIEWED

  • Chief adviser’s Special Envoy for International Affairs and Adviser Lutfey Siddiqi
    Fake documents submission behind visa complications for Bangladeshis: Lutfey Siddiqi
  • History in women's football: Bangladesh qualify for Asian Cup for the first time
    History in women's football: Bangladesh qualify for Asian Cup for the first time
  • Electric power transmission pylon miniatures and Adani Green Energy logo are seen in this illustration taken, on 9 December 2022. Photo: Reuters
    Bangladesh clears all dues to Adani Power
  • What it will take to merge crisis-hit Islamic banks
    What it will take to merge crisis-hit Islamic banks
  • A file photo of the NBR Bhaban in Agargaon, Dhaka
    NBR officers gripped by fear as govt gets tough  
  • NBR Office in Dhaka. File Photo: Collected
    Govt sends 4 senior NBR officials on forced retirement

Related News

  • UN report identifies the drugs most prevalent worldwide
  • Govt yet to bring drug abuse and corruption under control: Home adviser
  • Philippine Navy seizes $175 million meth haul at sea
  • Health reform commission, drug ingredient makers push for pharma self-reliance
  • Trump says US will soon announce tariffs on pharmaceutical imports

Features

Illustration: TBS

Why rare earth elements matter more than you think

3h | The Big Picture
Illustration: TBS

The buildup to July Uprising: From a simple anti-quota movement to a wildfire against autocracy

1d | Panorama
Illustration: TBS

Ulan Daspara: Remnants of a fishing village in Dhaka

3d | Panorama
Photo: Collected

Innovative storage accessories you’ll love

4d | Brands

More Videos from TBS

Patiya Police Station OC Withdrawn Amid Protests: What Experts Are Saying

Patiya Police Station OC Withdrawn Amid Protests: What Experts Are Saying

1h | Podcast
"We are not numbers... we are people... we are hungry."

"We are not numbers... we are people... we are hungry."

2h | TBS Stories
Violence against women and children at epidemic level: Advisor

Violence against women and children at epidemic level: Advisor

3h | TBS Stories
Appropriate action will be taken against army personnel involved in disappearances: AHQ

Appropriate action will be taken against army personnel involved in disappearances: AHQ

4h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net